Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL3920882 | 0.87 | ADORA1 (0.48) | VCP | |
| SCHEMBL3290820 | 0.82 | ADORA1 (0.61) | VCP | |
| SCHEMBL3290826 | 0.82 | ADORA1 (0.61) | VCP | |
| SCHEMBL3285909 | 0.74 | VCP (0.39) | VCP | |
| SCHEMBL3285905 | 0.74 | VCP (0.39) | VCP | |
| SCHEMBL3285910 | 0.74 | VCP (0.39) | VCP | |
| SCHEMBL1292139 | 0.73 | VCP (0.53) | VCP | |
| SCHEMBL29947079 | 0.73 | TRIM58 (0.44) | VCP | |
| SCHEMBL21621245 | 0.73 | TRIM58 (0.44) | VCP | |
| Bicarbonate SCHEMBL3908301 | 0.71 | ADORA1 (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024340-B1 | 4,5-DIPHENYL-PYRIMIDINYL-AMINO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI SA (FR) | 2012-07-18 | — | — | EP | disclosed |
| US-7713988-B2 | 4,5-diphenyl-pyrimidinylamino substituted carboxylic acids, method for the production and use thereof as medicaments | SANOFI-AVENTIS (FR) | 2010-05-11 | — | — | US | disclosed |
| US-20090149487-A1 | 4,5-DIPHENYL-PYRIMIDINYLAMINO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
| EP-2024340-A1 | 4,5-DIPHENYL-PYRIMIDINYL-AMINO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis (FR) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007131620-A1 | 4,5-DIPHENYL-PYRIMIDINYL-AMINO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149487-A1 | 4,5-DIPHENYL-PYRIMIDINYLAMINO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | GPR119, DPP4, SLC5A1 | VCP 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.